Mira Pharmaceuticals (MIRA) Debt to Equity (2022 - 2023)
Mira Pharmaceuticals' (MIRA) quarterly Debt to Equity came in at $1.51 in Q2 2023, up 775.14% quarter-over-quarter from -$0.22 in Q4 2022.
Mira Pharmaceuticals (MIRA) Debt to Equity (2022 - 2023) Analysis & Trends
Mira Pharmaceuticals has disclosed Debt to Equity across 2 years of filings, most recently posting $1.51 for Q2 2023.
- Debt to Equity for Q2 2023 came in at $1.51, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $1.51 (changed N/A YoY), and the FY2022 annual result was -$0.22, changed N/A from the prior year.
- Debt to Equity came in at $1.51 for Q2 2023 at Mira Pharmaceuticals, up from -$0.22 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.51 in Q2 2023 to a low of -$0.22 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.22 |
| 10 | Mira Pharmaceuticals | 23.69 Mn | 12.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.51 |
| Dec 31, 2022 | -0.22 |